--- title: Does brain stimulation improve movement nct_id: NCT07745673 phase: NA status: RECRUITING sponsor: Zhongnan Hospital study_type: INTERVENTIONAL canonical_url: "https://parkinsonspathways.com/trial/NCT07745673" clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT07745673" last_fetched: "2026-08-04T14:00:15.976Z" source: "Parkinson's Pathways (curated)" --- # Does brain stimulation improve movement **Goal (in five words):** Does brain stimulation improve movement **Official Title:** Comparative Efficacy of Temporal Interference Stimulation at Different Targets in Parkinson's Disease **Trial ID:** [NCT07745673](https://clinicaltrials.gov/study/NCT07745673) ## Key Facts - **Phase:** NA - **Status:** RECRUITING - **Study Type:** INTERVENTIONAL - **Sponsor:** Zhongnan Hospital - **Target Enrollment:** 18 participants - **Start Date:** 2026-06-29 - **Completion Date:** 2027-01-31 - **Conditions:** PARKINSON DIS - **Interventions:** TIS-STN, TIS-GP - **Intervention Types:** DEVICE - **Registry Record Last Updated:** 2026-08-04 (this month) ## Summary For Families Researchers are testing whether using temporal interference stimulation at one deep brain area versus another gives different improvements in movement and different changes on brain scans and electrical brain signals in Parkinson's. The treatment is daily 20-minute sessions for seven days of temporal interference stimulation aimed at either the subthalamic nucleus or the globus pallidus internus, with motor scores measured before and after each session and resting-state brain scans and 64-channel EEG done before and after the week. The trial is looking for people aged 40 or older with idiopathic Parkinson's who have responded well to dopamine replacement like levodopa, are in early to mid stages (Hoehn and Yahr 1.5, 2.5), can walk on their own for at least five minutes, have had the disease at least two years, and have stable medications. Safety will be followed by watching for side effects and any local skin reactions during the intervention. **Estimated commitment:** Moderate commitment estimated from the protocol (based on: 20 study visits). This reflects time and procedures only — confirm details with the study coordinator. ## What This Actually Involves **Placebo** _(From the protocol)_: There is no placebo group. Everyone receives an active treatment; the study compares one treatment against another. **Visits** _(From the protocol)_: You will have one 20-minute TIS session each day for 7 consecutive days, and resting-state fMRI and 64-channel EEG will be done before the first session and immediately after the 7-day intervention. > "Participants will receive one 20-minute TIS session daily for 7 consecutive days. Motor symptoms will be assessed using the MDS-UPDRS Part III immediately before and after each daily stimulation session. Resting-state functional magnetic resonance imaging (fMRI) and 64-channel electroencephalography (EEG) will be performed before the first stimulation session and immediately after completion of the 7-day intervention." **Procedures** _(From the protocol)_: - MRI scan (Non-invasive) > "Resting-state functional magnetic resonance imaging (fMRI) and 64-channel electroencephalography (EEG) will be performed before the first stimulation session and immediately after completion of the 7-day intervention." - Brain wave recording (EEG) (Non-invasive) > "Resting-state functional magnetic resonance imaging (fMRI) and 64-channel electroencephalography (EEG) will be performed before the first stimulation session and immediately after completion of the 7-day intervention." **Washout** _(Ask the coordinator)_: Ask the coordinator whether you would need to stop or pause any of your current medications before or during the study (a washout period), and for how long. **Travel & reimbursement** _(Ask the coordinator)_: Ask the coordinator whether travel, parking, or your time is reimbursed or compensated, and what is covered. _Fields marked “From the protocol” come from the trial's registry record or quoted protocol text. Fields marked “Ask the coordinator” are not reliably available and should be confirmed directly._ ## Eligibility at a Glance Key requirements found in this trial's official criteria, in plain language. Only what the listing states is shown; the study team makes the final call. - **Disease stage:** Hoehn and Yahr stage 1.5 to 2.5 - **Levodopa:** Must be taking levodopa (criteria text: "Previous or current treatment with dopamine replacement therapy (e.g., levodopa) with good response;") - **Medication dose:** Must be on a stable dose of Parkinson's medication (criteria text: "Stable medication regimen for at least 4 weeks prior to the study;") - **Time since diagnosis:** Diagnosed at least 2 years ago (criteria text: "disease duration >=2 years since diagnosis, clinically stable, and able to comply with study assessments and interventions") ## Do I Likely Qualify? — Self-Check Dimensions The trial page offers an interactive self-check built from this trial's parsed criteria. It covers these dimensions; anything the criteria don't state clearly is answered "ask the study coordinator", never assumed. - This trial enrolls people aged 40 or older. - This trial requires participants to be taking levodopa. - This trial requires a Parkinson's diagnosis at least 2 years ago. - This trial requires Hoehn and Yahr stage 1.5 to 2.5. ## Eligibility - **Minimum age:** 40 Years - **Sex:** ALL ### Full Criteria ``` Inclusion Criteria: 1. Adult males or females aged ≥40 years; 2. Diagnosis of idiopathic Parkinson's disease according to the UK Brain Bank criteria, with age of onset ≥40 years; 3. Previous or current treatment with dopamine replacement therapy (e.g., levodopa) with good response; 4. Hoehn and Yahr (H\&Y) stage 1.5-2.5; 5. Able to walk independently for at least 5 minutes without assistive devices; 6. No severe freezing of gait (FOG); 7. Disease duration ≥2 years since diagnosis, clinically stable, and able to comply with study assessments and interventions; 8. Stable medication regimen for at least 4 weeks prior to the study; 9. Signed informed consent form; subject or legal guardian is able to understand and willing to participate in this study. Exclusion Criteria: 1. Presence of other neurological disorders that may affect the study (e.g., ...); 2. Mild cognitive impairment or above (MoCA ≤23); 3. Orthopedic or other medical conditions that may affect gait or balance; 4. Contraindications to MRI, such as claustrophobia; 5. History of antipsychotic, antidepressant, or other medications that may affect dopamine levels; 6. History of other severe psychiatric disorders; 7. History of epilepsy, traumatic brain injury, or implanted metallic devices in the brain or heart (e.g., stimulators, pacemakers) or other contraindications; 8. History of electroconvulsive therapy (ECT); 9. Currently participating in other gait- or balance-related intervention training; 10. Physician-diagnosed cardiovascular risk factors for exercise. ``` ## Locations (1) - Zhongnan Hospital of Wuhan University, Wuhan, Hubei, China _(30.5833, 114.2667)_ - Bin Mei, (CONTACT), 02767812787, znyyll@126.com ## Central Contacts - Yang Pan, (CONTACT), 13952098253, panyang.zn@whu.edu.cn ## Making Contact: How to Call This Study Site ### Who to ask for Ask for the study coordinator. Some sites call this person the research coordinator. They are the right person for questions about joining a study. If you reach a front desk or a doctor's office scheduler, ask them to connect you with the research team for this study. ### What to say It is fine to read this out loud, word for word: > Hello, my name is ____. I am calling about a Parkinson's study at your site. The study number is NCT07745673. It is the one about "Does brain stimulation improve movement". Could I speak with the study coordinator about taking part? If you are calling for a family member, use their name and mention that you help with their care. ### What they will ask you - The year of diagnosis - Current medications and their doses - Other health conditions - Any procedures already done, such as deep brain stimulation (DBS) - How far you are able to travel for study visits - Whether a care partner can come to visits with you ### What to have ready - A written list of current medications and doses - Your neurologist's name and phone number - The diagnosis date. The year is enough. - A recent visit summary from the neurologist, if you have one ### What to ask them - How many visits are there, and how long does each visit take? The listing already answers this: You will have one 20-minute TIS session each day for 7 consecutive days, and resting-state fMRI and 64-channel EEG will be done before the first session and immediately after the 7-day intervention. Ask the coordinator to confirm it still applies. - Is travel, parking, or my time reimbursed? - Is there a placebo group, and what is my chance of being in it? The listing already answers this: There is no placebo group. Everyone receives an active treatment; the study compares one treatment against another. Ask the coordinator to confirm it still applies. - Would I need to stop or pause any of my current medications? - What happens when the study ends? Could I stay on the treatment if it helps? ### What to expect - Expect to wait a few days for a callback. A week is common. Calling or emailing again after that is fine and normal. - Many callers do not end up joining. Screening out is common and is not a judgment about you or your health. - Asking questions commits you to nothing. You can stop the process at any point. --- *Canonical: https://parkinsonspathways.com/trial/NCT07745673* *HTML version: https://parkinsonspathways.com/trial/NCT07745673* *Source data: https://clinicaltrials.gov/study/NCT07745673*